Bruker Corporation
BRKR
Rangering i aksjer
#2332
Bruker Corporation stands as a prominent global developer, manufacturer, and... Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Aksjekurs
$55.23
Markedsverdi
$8.42B
Endring (1 dag)
-0.25%
Endring (1 år)
44.93%
Land
US
Handel Bruker Corporation (BRKR)
Kategori
Healthcare
Antall utestående aksjer for Bruker Corporation (BRKR)
Antall utestående aksjer per June 2026: 152.20M
Ifølge Bruker Corporation sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 152.20M. Ved slutten av December 2024 hadde selskapet 149.00M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Bruker Corporation (BRKR) fra 2000 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 152.20M | 0.26% |
| 2025 | 151.80M | 1.88% |
| 2024 | 149.00M | 1.78% |
| 2023 | 146.40M | -1.48% |
| 2022 | 148.60M | -1.85% |
| 2021 | 151.40M | -1.30% |
| 2020 | 153.40M | -1.16% |
| 2019 | 155.20M | -0.64% |
| 2018 | 156.20M | -1.20% |
| 2017 | 158.10M | -2.04% |
| 2016 | 161.40M | -4.04% |
| 2015 | 168.20M | 0.24% |
| 2014 | 167.80M | 0.78% |
| 2013 | 166.50M | 0.30% |
| 2012 | 166.00M | 0.36% |
| 2011 | 165.40M | 0.61% |
| 2010 | 164.40M | 0.55% |
| 2009 | 163.50M | 0.49% |
| 2008 | 162.70M | 0.93% |
| 2007 | 161.20M | 58.80% |
| 2006 | 101.51M | 0.68% |
| 2005 | 100.82M | 4.62% |
| 2004 | 96.38M | -6.67% |
| 2003 | 103.26M | 96.31% |
| 2002 | 52.60M | -2.70% |
| 2001 | 54.06M | -3.89% |
| 2000 | 56.25M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 1.74B | 1,045.24% |
US
|
|
| 1.28B | 742.38% |
IE
|
|
| 383.50M | 151.97% |
US
|
|
| 1.48B | 870.83% |
US
|
|
| - | - |
DE
|
